Zealand Pharma A/S (Zealand) (CPH:ZEAL), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced on Friday the return by Boehringer Ingelheim of an Amylin analog that was being developed for the treatment of obesity and Type 2 diabetes.
Reportedly, the Amylin analog programme was licensed to Boehringer Ingelheim in 2014 to conduct and finance all clinical development and commercialisation, with Zealand eligible to receive milestone payments and royalties on global sales.
As of 20 March 2020, this license agreement will no longer be active. The long-term partnership will continue with the license agreement to develop the GLP-1/glucagon analog BI 456906, which is planned to advance into phase 2 development.
Zealand added that it will communicate the potential of further development of the Amylin programme at a later stage, following a thorough evaluation.
European Commission approves Camurus' once-monthly octreotide treatment for acromegaly
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
AbbVie agrees to acquire Capstan Therapeutics
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes